Ansell Ltd (ANN) Fair Value & Analysis
Healthcare · AU · Market cap A$4.4B (≈ $3.2B) · ISIN AU000000ANN9
What is Ansell Ltd really worth?
A solid business, but trading 188% above our fair value of A$14.67.
Strengths
Risks
For context
Fair value as of: Aug 20, 2026
From 24 valuation models · updated 16 days ago
Share price +26.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (A$18.34). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range A$19.18 – A$42.30 · fair‑value band A$10.46 – A$18.34 · the A$42.26 price screens above the A$14.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Ansell Ltd (ANN) currently trades at A$42.26, while our model-based Fair Value estimate is A$14.67, implying the stock looks roughly 188.0% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of A$12.27 per share, and 0 of the 24 models we run sit above the A$42.26 price. Bear case: the Earnings-Based group reads lowest at A$2.30, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Ansell Ltd generated revenue of A$2.0B at a net margin of 6.7%. Revenue grew 0.7% year over year. It earns a return on equity of 7.0%. Net debt stands at A$567M. Fundamentals as of Aug 20, 2026
Our scenario range runs from A$10.46 (bear case) to A$18.34 (bull case); at A$42.26, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 69% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at −65%, ANN screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 12 months have passed since. In that time the company retained roughly A$0.5453 per share, which is 3.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Multiples (A$12.27) versus Earnings-Based (A$2.30). Highest evidence: FCF DCF (79).
Notify me when ANN reaches fair value
Put ANN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 77
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates through two segments: Healthcare and Industrial.
Full company description
Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates through two segments: Healthcare and Industrial. The Healthcare segment manufactures and markets solutions, including surgical gloves, single-use and examination gloves, and clean and sterile gloves and garments, as well as consumables for hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for various industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, utilities, logistics, and first responders. It sells provides its products under ActivArmr, AlphaTec, BioClean, EDGE, ENCORE, GAMMEX, HyFlex, Kimtech, KleenGuard, MICROFLEX, MICRO-TOUCH, RINGERS, SANDEL, TouchNTuff, and VIKING brands. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ansell Ltd reported revenue of $2.0B in FY2025 versus $2.0B in FY2021, a compound −0.3%/yr. Reported net income was $102M in FY2025, compounding −19.9%/yr from FY2021.
of which total revenue +1.6 % · buybacks/dilution +1.2 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
ANN screens 188% overvalued. Compare with Intuitive Surgical, Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Personal Protective Equipment (PPE) Global Market Forecast to 2031 Featuring 3M, Protective Industrial Products, Ansell, DuPont de Nemours,
- Personal Protective Equipment Market to Reach USD 34.22 Billion by 2031 | 3M, DuPont, Ansell, MSA, and 37 Key Players Profiled | Arizton
- Ansell Announces Greenovation(TM) Awards for Sustainability Leadership and Waste Reduction
- Ansell Limited's (ASX:ANN) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
Peer Group
Medical Instruments & Supplies · 194 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | −59% |
| EssilorLuxottica Société anonyme EL | €160.35 | €94.93 | −41% |
| Medline Inc MDLN | $36.59 | $30.15 | −18% |
| Becton, Dickinson and Company BDX | $187.12 | $100.46 | −46% |
| Alcon Inc ALC | $72.23 | $39.78 | −45% |
| ResMed Inc RMD | A$33.19 | A$26.23 | −21% |
| West Pharmaceutical Services, Inc WST | $337.47 | $141.58 | −58% |
| Sartorius Stedim Biotech S.A DIM | €197.70 | €48.88 | −75% |
| Straumann Holding STMN | CHF 97.38 | CHF 47.31 | −51% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | −75% |
Compare Ansell Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ansell Ltd (ANN) overvalued or undervalued?
What is the fair value of ANN?
What is the quality score of ANN?
What is the revenue of Ansell Ltd (ANN)?
What is the net profit margin of ANN?
Does Ansell Ltd pay a dividend?
Watch Ansell Ltd in the live analysis
One click puts Ansell Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.